Latest News
Giredestrant vs Other Oral SERDs: How Roche’s Wilserdly Compares
Giredestrant has become the latest oral SERD approved in the US for ESR1-mutated breast cancer. It joins elacestrant, imlunestrant and camizestrant. Its distinguishing feature is the partner drug. It is the only one of the four approved alongside everolimus. The...
Latest News
Too Good to Be True: The Case for Honest Medical-AI Benchmarks
Every researcher who trains medical-imaging models knows the moment. The training run finishes, the metric appears, and it is not just good, it is startlingly good. Accuracy in the high nineties. A segmentation score well beyond anything in published medical AI...
Clinical Trial Results 20 November 2026
Clinical trial results 20 November 2026 span acute myeloid leukaemia, type 3 Gaucher disease, bladder cancer, depression and Alzheimer’s disease. SELLAS Life Sciences’ galinpepimut-S met its overall survival primary endpoint in acute myeloid leukaemia. The FDA...
EU Fragrance Allergen Rules: More Than a Labelling Change
At first glance, the EU’s updated rules on fragrance allergens seem straightforward. More ingredients need to be listed on cosmetic labels. For formulators and brands, though, the real work begins long before the label is printed. It starts with supplier data, runs...
Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares
Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi,...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The Synthetic Patient Problem: AI Risks Removing Patients from Healthcare
I spent years in pharma, biotech and genomics, in commercial, market access and training roles. I sat in a lot of rooms where smart people talked about patients. Too often, no patient sat in the room. Today, the synthetic patient is starting to take that place. I also...
Pfizer Starna Deal: What Does Pfizer Get for $330 Million Upfront?
The Pfizer Starna deal gives Pfizer three early in vivo CAR-T programmes for autoimmune diseases, for $330 million upfront. Pfizer announced the exclusive licensing agreement with Starna Therapeutics on 18 November 2026. Starna is eligible for up to $2.3 billion in...
Treatment Escalation Is a Decision Pathway, Not a Single Choice
Clinical guidelines tell physicians when to reassess a chronic disease. They say far less about how to reason at each reassessment, which is where treatment escalation decisions are made. An illustrative rheumatoid arthritis case shows where that gap opens, and what...
Isomorphic Labs Clinical Trial: When Will Its AI-Designed Drugs Start?
The first Isomorphic Labs clinical trial has no public start date as of 18 November 2026. In January, founder and chief executive Sir Demis Hassabis targeted first trials by the end of 2026. The company’s newest statement does not repeat that date. That statement came...
Weaker or Just Lighter? The Measurement GLP-1 Weight Loss Is Missing
Body-composition scans report how much lean mass a patient loses on semaglutide or tirzepatide. They do not report whether the patient got weaker. That can be measured in about fifteen minutes. Ask a patient on a GLP-1 drug how treatment is going and you will hear a...
COINS Act Biotech Rule: Does It Cover China Licensing Deals?
Treasury’s own guidance says its proposed COINS Act biotech rule does not list a standalone licence as covered. The final text will decide. Treasury released the proposal on 22 October 2026, and it would add biotechnology to the US outbound investment programme. The...
Beyond Brain Organoids: What Makes a CNS Drug Screening Hit Credible?
Summary: Human iPSC-derived neurons and brain organoids are expanding opportunities for CNS drug screening. However, identifying a promising compound is only the beginning. Creative Biolabs highlights how disease-relevant neuronal models, multiparametric phenotypic...
OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares
How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...
Ollin Biosciences Acquisition: What Is J&J Paying and What Does It Get?
Johnson & Johnson (J&J) will pay $2.2 billion upfront in the Ollin Biosciences acquisition. Up to about $1.125 billion more is payable in milestones. The deal brings OLN324, a bispecific antibody for wet age-related macular degeneration (AMD) and diabetic...
Why Biotechs Hire Quality and Regulatory Too Late, and What It Costs Them
In short: Most early-stage biotechs bring in their first permanent Quality or Regulatory hire later than they should, often only when an audit, a funding milestone or a submission is close. Hiring Quality and Regulatory people earlier costs less over time, makes...
Alzheimer’s Blood Tests: How Close Is Routine Screening?
For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...
Deramiocel FDA Decision: Can Capricor Win Approval in Duchenne?
The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in...
The Synthetic Patient Problem: AI Risks Removing Patients from Healthcare
I spent years in pharma, biotech and genomics, in commercial, market access and training roles. I sat in a lot of rooms where smart people talked about patients. Too often, no patient sat in the room. Today, the synthetic patient is starting to take that place. I also...
Pfizer Starna Deal: What Does Pfizer Get for $330 Million Upfront?
The Pfizer Starna deal gives Pfizer three early in vivo CAR-T programmes for autoimmune diseases, for $330 million upfront. Pfizer announced the exclusive licensing agreement with Starna Therapeutics on 18 November 2026. Starna is eligible for up to $2.3 billion in...
Treatment Escalation Is a Decision Pathway, Not a Single Choice
Clinical guidelines tell physicians when to reassess a chronic disease. They say far less about how to reason at each reassessment, which is where treatment escalation decisions are made. An illustrative rheumatoid arthritis case shows where that gap opens, and what...
Isomorphic Labs Clinical Trial: When Will Its AI-Designed Drugs Start?
The first Isomorphic Labs clinical trial has no public start date as of 18 November 2026. In January, founder and chief executive Sir Demis Hassabis targeted first trials by the end of 2026. The company’s newest statement does not repeat that date. That statement came...
Weaker or Just Lighter? The Measurement GLP-1 Weight Loss Is Missing
Body-composition scans report how much lean mass a patient loses on semaglutide or tirzepatide. They do not report whether the patient got weaker. That can be measured in about fifteen minutes. Ask a patient on a GLP-1 drug how treatment is going and you will hear a...
COINS Act Biotech Rule: Does It Cover China Licensing Deals?
Treasury’s own guidance says its proposed COINS Act biotech rule does not list a standalone licence as covered. The final text will decide. Treasury released the proposal on 22 October 2026, and it would add biotechnology to the US outbound investment programme. The...
Beyond Brain Organoids: What Makes a CNS Drug Screening Hit Credible?
Summary: Human iPSC-derived neurons and brain organoids are expanding opportunities for CNS drug screening. However, identifying a promising compound is only the beginning. Creative Biolabs highlights how disease-relevant neuronal models, multiparametric phenotypic...
OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares
How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...
Ollin Biosciences Acquisition: What Is J&J Paying and What Does It Get?
Johnson & Johnson (J&J) will pay $2.2 billion upfront in the Ollin Biosciences acquisition. Up to about $1.125 billion more is payable in milestones. The deal brings OLN324, a bispecific antibody for wet age-related macular degeneration (AMD) and diabetic...
Why Biotechs Hire Quality and Regulatory Too Late, and What It Costs Them
In short: Most early-stage biotechs bring in their first permanent Quality or Regulatory hire later than they should, often only when an audit, a funding milestone or a submission is close. Hiring Quality and Regulatory people earlier costs less over time, makes...
Alzheimer’s Blood Tests: How Close Is Routine Screening?
For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...
Deramiocel FDA Decision: Can Capricor Win Approval in Duchenne?
The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in...
Featured Articles
Further News
Ivonescimab FDA Approval: What the Complete Response Letter Means
The FDA has declined to approve ivonescimab for EGFR-mutated lung cancer, Summit Therapeutics said on Sunday 15 November 2026. The agency issued a complete response letter, so ivonescimab FDA approval is not in place in this setting. The goal date had been Saturday 14...
Environmental Cost of AI and ML in Life Science: Is It Bad for the Planet?
During a lab internship, I spent three months counting cells under a microscope. One slide at a time, one cell at a time. Today a trained model can do that counting in seconds, and that speed raises a question about the environmental cost of AI. That is the promise of...
Efficiency vs. Resilience: The Defining Life Sciences Battle of 2027
Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience. In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are...
Weekly News Roundup | 16 November 2026
Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...
Why Did Pelacarsen Fail? What Lp(a)HORIZON Means for Lp(a) Drugs
Why did pelacarsen fail, when the drug did exactly what it was designed to do? Novartis’s antisense therapy lowered lipoprotein(a), or Lp(a), by an estimated 77.7 percentage points more than placebo at one year. Yet heart attacks, strokes, urgent coronary procedures...
Home Pregnancy and Ovulation Tests: The Result Is Only Half the Job
Imagine someone using a home pregnancy test exactly as instructed. They take the sample, check the result within the stated time and see a negative result. But they tested before pregnancy hormone levels were high enough to detect. The test may have worked as...
Clinical Trial Results 13 November 2026
Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...
NICE Cost-Effectiveness Threshold: What Has Changed Six Months On?
The NICE cost-effectiveness threshold rose on 31 March 2026, the first increase in more than two decades. Six months on, early data suggest appraisal committees are using the wider range in full. Recommendation rates have risen, and fewer companies are walking away...
Risto-cel Approval: When Could Beam’s Sickle Cell Therapy Reach Patients?
Beam Therapeutics plans to file for US risto-cel approval as early as year-end 2026. Under the FDA’s published review goals, a decision would follow roughly eight to 12 months after submission. No FDA action date has been announced. The plan follows positive topline...
argenx Unnatural Products Deal: What Does $550 Million Upfront Buy?
The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595...
Beyond the Magic Marker: What EEG Could Add to ADHD Assessment
The search for a single brainwave test for ADHD has largely failed. But that was always the wrong goal. The more useful question is whether EEG, used alongside clinical assessment, could add information that helps make ADHD assessment more accurate and treatment more...
From GLP-1 Trial Results to the Follow-Up Visit
A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.












